New CEO and new Chairman of the Board at Q-Med AB
(Thomson Reuters ONE) -
Bengt Ågerup leaves his position as CEO of Q-Med. The Board has appointed Maria
Carell as his successor, as was presented in a press release on April 27, 2010.
Anders Milton, who has been a member of Q-Med's Board since 1997 and Chairman
since 2009, has at his own request resigned as Chairman of the Board but is
staying on as a member of the Board. The Board has appointed Bengt Ågerup as the
new Chairman of the Board up until the next Annual General Meeting.
With his specialist knowledge, Bengt Ågerup will have an Executive Chairman
role.
Anders Milton says "I think that it is natural that Bengt Ågerup as the
principal owner is the Chairman of the Board. I will continue my work as a
member of the Board and try to contribute to Q-Med's high quality products
continuing to develop and reach even more women and men. Q-Med's products are
the gold standard of the industry. Together with our partners, doctors and
nurses we will make our products more accessible, both emotionally and
practically."
"Anders has done a fantastic job with the Board, which is a blend of the new and
the old, and it will be a great pleasure to lead it. Maria Carell will be an
excellent successor to me, full of energy and belief in the future. Q-Med faces
an exciting future full of strategic alternatives in great need of constructive
collaboration," says Bengt Ågerup.
Queries should be addressed to:
Bengt Ågerup, Chairman of the Board
Tel: +46 70 974 9025
Anders Milton, Member of the Board
Tel: +46 70 526 46 02
Q-Med AB is a medical device company that develops, manufactures, markets, and
sells high quality medical implants for esthetic and medical use. The majority
of the products are based on the company's patented technology, NASHA(TM), for
the production of stabilized non-animal hyaluronic acid. The product portfolio
today contains: Restylane® for filling lines and folds, contouring and creating
volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the
treatment of osteoarthritis of the hip and knee joints, Deflux® for the
treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder)
in children, and Solesta® for the treatment of fecal incontinence. Sales are
made through the company's own subsidiaries or distributors in over 70
countries. Q?Med today has about 650 coworkers, with almost 400 at the company's
head office and production facility in Uppsala, Sweden. Q-Med AB is listed in
the Mid Cap segment of the NASDAQ OMX Nordic.
Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail:info(at)q-med.com. Web:
www.q-med.com
[HUG#1441833]
Press release:
http://hugin.info/130306/R/1441833/386139.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Q-Med AB via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 01.09.2010 - 08:06 Uhr
Sprache: Deutsch
News-ID 40813
Anzahl Zeichen: 0
contact information:
Town:
Uppsala
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 210 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"New CEO and new Chairman of the Board at Q-Med AB"
steht unter der journalistisch-redaktionellen Verantwortung von
Q-Med AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
